Wuhan General Group Launches Mental Illness Drug Discovery Company Neurai Life Sciences
Wuhan General Group, Inc. (OTC PINK:WUHN) has announced the launch of Neurai Life Sciences, a biotechnology company focused on developing therapies for mental health disorders. Neurai will utilize artificial intelligence for drug discovery and aims to address issues such as major depressive disorder, anxiety, and addiction. The company has appointed Dr. Riyad Domingo as CEO, who emphasizes inclusivity in drug development. Neurai is set to initiate a capital raise to fund preclinical research and has plans for future shareholder events.
- Launch of Neurai Life Sciences aims to develop innovative therapies for mental health disorders.
- Utilization of artificial intelligence in drug discovery represents a cutting-edge approach.
- Appointment of Dr. Riyad Domingo as CEO brings expertise in drug discovery.
- None.
CAPE TOWN, SA / ACCESSWIRE / January 19, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Wuhan General Group, Inc./M2Bio Sciences, Inc. is excited to announce the launch of Neurai Life Sciences.
Neurai Life Sciences is a pre- and clinical-stage biotechnology company focusing on the drug discovery and development of next generation therapies treating mental health disorders. The company will lead the industry in artificial intelligence-driven target discovery, innovative and sustainable small molecule chemistry, and inclusive clinical development in the pursuit of novel therapeutics for major depressive disorder, anxiety disorders, and addiction. Neurai Life Sciences is primed to realize the infinite potential of targeted therapeutics within the brain serotonin receptor-mediated signaling pathways.
With the goal of hiring the best international talent, Neurai Life Sciences has recruited Riyad Domingo Ph.D. as Chief Executive Officer. Dr. Domingo is the current Harvard South Africa Fellow for 2021-2022 and holds a doctorate in Medical Biochemistry with a focus on drug discovery and development from the Institute of Infectious Diseases and Molecular Medicine at the University of Cape Town.
"The consequences of the COVID-19 pandemic have underscored the need for the advancement of neuropsychiatric medicine. Mental illness affects everyone, so we at Neurai believe that our targeted drug development process should consider and include all individuals, independent of age, race, or gender. We leverage emerging technologies including machine learning and novel formulation methods, accompanied by well-established industry approaches, thereby driving the evolution of the mental health industry and how therapeutics are developed in the future. This is absolutely vital for the future of our mental health." said Dr. Domingo.
Jeff Robinson, Wuhan General Inc, CEO added: "Neurai Life Sciences will pioneer a new field of neuropsychiatric medicine. The company will revolutionize and challenge conventional approaches to developing and treating mental health conditions with new medicines and therapies. With Dr. Domingo at the helm, we know that these new technologies will change the lives of millions globally. Neurai is recruiting the brightest minds in the fields of AI and pharma to further complement the ground-breaking technologies and portfolio of molecular assets that are currently in development under Neurai Life Sciences. Never has there been a greater need to combine technology and medicine to address the global mental illness pandemic."
At this time, Neurai Life Sciences is a private company and
All Wuhan General Inc. shareholders interested in investing in the capital raise for Neurai Life Sciences or for further information, contact Jeff Robinson, Chief Executive Officer, at jeff@m2bio.co or our web site found here. It is anticipated Neurai Life Sciences will seek a liquidity event for its shareholders at a later date. More details to follow.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
Publicly traded company (OTC Pink: WUHN)
Website: www.neurai.life
E-mail: info@neurai.life
Follow us on LinkedIn: Neurai Life Sciences
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on YouTube: https://www.youtube.com/channel/M2BioSciences
Follow us on Instagram: https://www.instagram.com/m2bio.sciences
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/684558/Wuhan-General-Group-Launches-Mental-Illness-Drug-Discovery-Company-Neurai-Life-Sciences
FAQ
What is Neurai Life Sciences and what is its focus?
Who has been appointed as CEO of Neurai Life Sciences?
How will Neurai Life Sciences fund its research?
What therapeutic areas will Neurai Life Sciences address?
What is the stock symbol for Wuhan General Group?
